Seeking Alpha

DPRX
Dipexium Pharmaceuticals, LLC - NASDAQ

4/18/2014, 6:41 AM ET
Quote & Analysis Breaking News StockTalk
dprx chart
Today 5d 1m 3m 1y 5y 10y
52wk high:  
52wk low:  
EPS:  
PE (ttm):  
Div Rate:  
Yield:  
Market Cap:  
Volume:  
FOCUS  |  RELATED  |  TRANSCRIPTS  |  OTHER NEWS & PR
  • IPO Preview: Dipexium Pharmaceuticals
    IPOdesktop Thu, Mar. 13 1 Comment

    Summary

    • Late stage pharmaceutical company.
    • Locilex™ is initially being targeted for the treatment of mild infections of diabetic foot ulcers.
    • DPRX believes that Locilex™ may be approved by the FDA within 24 months of commencing Phase 3 enrollment, scheduled for Q2 2014.
  • Dipexium Pharmaceuticals IPO Could Be A Cure-All For This Emerging Biotech Company
    Don Dion Wed, Mar. 12 6 Comments

    Summary

    • New York-based DPRX is a pharmaceutical firm in the process of developing and commercializing a topical, broad spectrum antibiotic.
    • DPRX plans to raise $30 million in its upcoming IPO, offering 2.3 million shares at an expected price range of $12.00-$14.00 per share.
    • We rate this IPO a Buy, given the likelihood DPRX's lead product candidate will gain FDA approval and a relative lack of debt.
There are no Transcripts on DPRX.
There are no News articles on DPRX.
DPRX vs. ETF Alternatives
Company Description

Dipexium Pharmaceuticals Inc is a biopharmaceutical company. It develops and markets Locilex (tm) which is a topical antibiotic. The Company is in development stage.

Sector: Healthcare
Industry: Biotechnology
Country: United States
OTHER NEWS